{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:13:38Z","timestamp":1792700018405,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Dermatol Online J"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/idoj.idoj_169_19","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T04:00:25Z","timestamp":1638763225000},"page":"51","source":"Crossref","is-referenced-by-count":13,"title":["Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe Psoriasis"],"prefix":"10.4103","volume":"11","author":[{"given":"BelaJ","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deval","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-5178.275672-1","first-page":"136","volume-title":"Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction","author":"Stern","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"key-10.4103\/2229-5178.275672-2","first-page":"377","volume-title":"Global epidemiology of psoriasis: A systematic review of incidence and prevalence","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.275672-3","first-page":"1197","volume-title":"Psoriasis","author":"Lebwohl","year":"2003","journal-title":"Lancet"},{"key":"key-10.4103\/2229-5178.275672-4","first-page":"140","volume-title":"Quality of life in patients with psoriasis: A systematic literature review","author":"de","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"key-10.4103\/2229-5178.275672-5","first-page":"218","volume-title":"The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004","author":"Kurd","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.275672-6","first-page":"137","volume-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6.Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions","author":"Menter","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.275672-7","first-page":"95","volume-title":"Consensus guidelines for the management of plaque psoriasis","author":"Hsu","year":"2012","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/2229-5178.275672-8","first-page":"1867","volume-title":"Current and emerging systemic treatment strategies for psoriasis","author":"Laws","year":"2012","journal-title":"Drugs"},{"key":"key-10.4103\/2229-5178.275672-9","first-page":"649","volume-title":"Treatment of psoriasis: Part 2.Systemic therapies","author":"Lebwohl","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.275672-10","first-page":"2","volume-title":"Evidence-based recommendations on conventional systemic treatments in psoriasis: Systematic review and expert opinion of a panel of dermatologists","author":"Paul","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.275672-11","first-page":"451","volume-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis","author":"Menter","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.275672-12","first-page":"365","volume-title":"Comparative effectiveness of biologics in psoriasis","author":"Kim","year":"2012","journal-title":"Am J Clin Dermatol"},{"key":"key-10.4103\/2229-5178.275672-13","first-page":"1180","volume-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: Findings from the National Psoriasis Foundation Surveys, 2003-2011","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"key-10.4103\/2229-5178.275672-14","doi-asserted-by":"crossref","unstructured":"Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: Results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol 2014;70:871-81.e1-30.","DOI":"10.1016\/j.jaad.2013.12.018"},{"key":"key-10.4103\/2229-5178.275672-15","first-page":"2002","volume-title":"Physician perspectives in the management of psoriasis and psoriatic arthritis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey","author":"van","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.275672-16","first-page":"1393","volume-title":"Apremilast: A review in psoriasis and psoriatic arthritis","author":"Deeks","year":"2015","journal-title":"Drugs"},{"key":"key-10.4103\/2229-5178.275672-17","first-page":"37","volume-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Effectiveness and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.275672-18","first-page":"1387","volume-title":"Effectiveness and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: A phase III, randomized controlled trial (ESTEEM 2)","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.275672-19","first-page":"290","volume-title":"Effectiveness and safety of apremilast monotherapy for moderate to severe psoriasis: Retrospective study","author":"Ighani","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"key-10.4103\/2229-5178.275672-20","first-page":"1173","volume-title":"Real-world data on the effectiveness and safety of apremilast in patients with moderate-to-severe plaque psoriasis","author":"Papadavid","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.275672-21","first-page":"254","volume-title":"Apremilast in psoriasis \u2013 A prospective real-world study","author":"Vujic","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.275672-22","first-page":"674","volume-title":"Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis","author":"Wong","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"key-10.4103\/2229-5178.275672-23","first-page":"145","volume-title":"Real-world experience with apremilast in treating psoriasis","author":"Mayba","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"key-10.4103\/2229-5178.275672-24","first-page":"623","volume-title":"A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study","author":"Ighani","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.275672-25","first-page":"1","volume-title":"Real-world data on the effectiveness and safety of apremilast in Japanese patients with plaque psoriasis","author":"Ohata","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"key-10.4103\/2229-5178.275672-26","first-page":"471","volume-title":"Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring","author":"Dogra","year":"2016","journal-title":"Indian Dermatol Online J","ISSN":"https:\/\/id.crossref.org\/issn\/2229-5178","issn-type":"print"},{"key":"key-10.4103\/2229-5178.275672-27","first-page":"278","volume-title":"Diagnosis and management of psoriasis","author":"Kim","year":"2017","journal-title":"Can Fam Physician"},{"key":"key-10.4103\/2229-5178.275672-28","unstructured":"Apremilast product monograph. Available from: https:\/\/media.celgene.com\/content\/uploads\/sites\/23\/Otezla-Product- Monograph-English.pdf. [Last accessed on 2019 Jan 10]."},{"key":"key-10.4103\/2229-5178.275672-29","first-page":"507","volume-title":"The effectiveness and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)","author":"Reich","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:24:01Z","timestamp":1787163841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.IDOJ_169_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["275672"],"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_169_19","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}